Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction

Published: Nov 8, 2021
Abstract
Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametinib in patients with advanced solid tumors who had various degrees of hepatic dysfunction (HD). Methods Advanced cancer patients were stratified into 4 HD groups based on Organ Dysfunction Working Group hepatic...
Paper Details
Title
Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction
Published Date
Nov 8, 2021
Journal
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.